News items related to: News
-
Thailand submits patent opposition on TB drug for children
Johnson & Johnson’s TB drug, bedaquiline (BDQ) can improve lives. The pediatric version is not substantially different to the adult...
-
Vietnam’s route to optimal, affordable HIV treatment
Following civil society advice, Vietnam’s Ministry of Health recommended TLD for HIV treatment. This was back in November 2019. Vietnam...
-
OPINION: Breaking a ‘vicious cycle’ of overpaying for HIV drugs in Ukraine
“In November 2020, Ukraine finally shifted from the overpriced branded version of darunavir (DRV) to the more affordable generic version of...
-
HIV activists are essential to the COVID-19 response
The legacy of HIV activism is approaching a 40-year history, one which is inextricably linked with the actions of pharmaceutical...
-
COVID-19 vaccine announcements: Our view
Following on from the BioNTech and Pfizer vaccine announcement earlier this month, where we expressed cautious optimism, but also the...
-
Who will get Pfizer’s COVID-19 vaccine?
BioNTech and Pfizer have announced today that their vaccine candidate has, so far, been found to be more than 90%...
-
Russian government advised – “issue compulsory license to make generic COVID-19 drug available”
First civil society, and now a generic drug company, have asked the Russian government to issue a compulsory license on...
-
TB: 9 patent oppositions against J&Js overpriced drugs
1.2 million lives were lost to TB last year. The reduction in TB deaths annually is slow, and even these...
-
HIV2020 video: Community reclaiming the global response!
The Treatment Activist Meeting took place last week, as part of HIV2020 Online. HIV2020 is described as a key population-led, inter-disciplinary,...
-
Join the #HIV2020 Activist Meeting – this Tuesday
Please join us at the HIV2020 Treatment Activist Meeting on Tuesday 6th October! Register by Sunday 4th October. The history of the HIV...
-
HIV: Switch to generic darunavir in Kyrgyzstan and save $53,000
First published by the Partnership Network Association in Kyrgyzstan, read here in Russian. Analysis carried out by our campaign partner,...
-
Indian Patent Office: Merck’s patent application for HIV drug, raltegravir, is “refused”
A patent that Merck has been pursuing in India since 2007 has been refused by the Indian Patent Office. The...